1. Scrip
  2. >>Drug Pricing

Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018

 
• By Cathy Kelly

Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for Lilly and Janssen.

US-Money-and-Pills_V2_1200x675

In response to ongoing pressure from the public and policymakers, three big pharmas scaled back average list price increases across their US drug portfolios in 2018, according to recently released data.

Eli Lilly & Co., Merck & Co. Inc. and Janssen Pharmaceutical Cos. are all reporting that list prices rose in the mid-single digit range in 2018, continuing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.